Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome

In patients with hypereosinophilic syndrome (HES), mepolizumab reduces the incidence of HES-related clinical signs and symptoms (flares). However, reports characterizing flare manifestations are limited. The double-blind, parallel-group 200622 trial (NCT02836496) enrolled patients ≥12 years old with...

Descripción completa

Detalles Bibliográficos
Autores principales: Pane, Fabrizio, Lefevre, Guillaume, Kwon, Namhee, Bentley, Jane H., Yancey, Steven W., Steinfeld, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462399/
https://www.ncbi.nlm.nih.gov/pubmed/36091012
http://dx.doi.org/10.3389/fimmu.2022.935996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462399/
https://www.ncbi.nlm.nih.gov/pubmed/36091012
http://dx.doi.org/10.3389/fimmu.2022.935996

Ejemplares similares